Table 1.
Patient and clinicopathological characteristics of the six patients evaluable for mutational analysis.
| Patient Characteristics | Clinicopathological Characteristics | Outcome | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | M/F | Age | Stage | IPI | Morphology | COO | Aberrant IHC | FISH | Primary Biopsy | Relapse Biopsy 1 | Relapse Biopsy 2 | End-of-Treatment | PFS (Months) | OS (Months) |
| 1 | F | 53 | 4 | 3 | DLBCL | GCB | n.a. | Inconclusive | Jejunum | Lymph node | - | CR | 7 | 101 |
| 2 | M | 45 | 2 | 2 | DLBCL | ABC | n.a. | MYC– | Lymph node | Lymph node | - | CR | 17 | 56 † |
| 3 | M | 65 | 3 | 2 | DLBCL | GCB | n.a. | MYC– | Soft tissue | Soft tissue | - | PR | 7 | 14 † |
| 4 | F | 57 | 3 | 1 | DLBCL | ABC | CD20– | MYC– | Lymph node | Lymph node | - | PD | 5 | 8 † |
| 5 | F | 57 | 4 | 4 | HGBCL MYC+/BCL6+ # | Unclassified | CD5+ | MYC+ BCL6+ |
Lymph node A | Lymph node B * | Lymph node C * | n.a. | 14 | 36 † |
| 6 | M | 79 | 1 | 2 | DLBCL | GCB | n.a. | MYC– | Soft palate | Skin site A ** | Skin site B ** | CR | 55 | 55 † |
Abbreviations: ABC, activated B-cell; COO, cell-of-origin as determined by the nCounter Lymph2Cx assay; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; FISH, fluorescence in situ hybridization; GCB, germinal center B-cell; IHC, immunohistochemistry; IPI, international prognostic index; n.a., not applicable; OS, overall survival; PFS, progression free survival; PR, partial remission. # According to the WHO 2017 classification the case is classified as a High grade B-cell lymphoma with MYC and BCL6 rearrangement; * biopsies taken at the different time points; ** biopsies taken at the same time points; † patient deceased.